ANEMIA;
CANCER PATIENT;
CANCER SURVIVAL;
DRUG SAFETY;
DYSPHAGIA;
HUMAN;
LETTER;
LUNG NON SMALL CELL CANCER;
NEPHROTOXICITY;
NEUTROPENIA;
OVERALL SURVIVAL;
PAIN;
Vinorelbine as first-line chemotherapy for metastatic breast carcinoma
Romero A., Rabinovich M.G., Vallejo C.T., et al. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 12 (1994) 336-341
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial
Gridelli C., Perrone F., Gallo C., et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 9 (2003) 362-372
Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors
Marty M., Fumoleau P., Adenis A., et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12 (2001) 1643-1649
A multicenter randomized phase II study of oral versus intravenous vinorelbine in advanced non-small-cell lung cancer patients
Jassem J., Ramlau R., Karnicka-Mlodkowska H., et al. A multicenter randomized phase II study of oral versus intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol 12 (2001) 1375-1381
Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy
Freyer G., Deloziert T., Lichinister M., et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 21 (2003) 35-40
Acute pain syndrome at tumour site in neoplastic patients treated with vinorelbine: report of unusual toxicity
Gebbia V., Testa A., Valenza R., et al. Acute pain syndrome at tumour site in neoplastic patients treated with vinorelbine: report of unusual toxicity. Eur J Cancer 30A 6 (1994) 889